As a druggable kinase, we further demonstrate using in vitro and ex vivo models of CRC that inhibition of AURKB with the small molecular weight prodrug AZD1152 enhanced sensitivity to 5-FU. The gene discussed is AURKB; the disease is colorectal carcinoma.